These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3085698)

  • 41. The nitroglycerin polymer gel matrix system: a new method for administering nitroglycerin evaluated with plasma nitroglycerin levels.
    Colfer H; Stetson P; Lucchesi BR; Wagner J; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(3):521-5. PubMed ID: 6177952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Post-marketing surveillance of the Transiderm-Nitro patch in general practice.
    Bridgman KM; Carr M; Tattersall AB
    J Int Med Res; 1984; 12(1):40-5. PubMed ID: 6420213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Facilitated intravenous access through local application of nitroglycerin ointment.
    Roberge RJ; Kelly M; Evans TC; Hobbs E; Sayre M; Cottington E
    Ann Emerg Med; 1987 May; 16(5):546-9. PubMed ID: 3105368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantitation of nitroglycerin in human blood after administration by sustained release.
    Givant Y; Sulman FG
    Experientia; 1978 May; 34(5):643-4. PubMed ID: 95967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Topical nitroglycerin ointment for treatment of acute hypertension in hospitalized inpatients.
    Brower KA; Garcia NA; Smith HL; Wall GC
    J Cardiovasc Pharmacol Ther; 2015 May; 20(3):284-8. PubMed ID: 25193736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug release rates from four sizes of a new transdermal nitroglycerin adhesive patch.
    Riedel DJ; Wick KA; Hawkinson RW; Kolars CA; Crowley JK; Harrison LI; de Dennis SR
    Clin Ther; 1989; 11(3):409-16. PubMed ID: 2501032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulatory effects of nitroglycerin ointment (Nitrong) with special reference to venous distensibility.
    Nyberg G; Panfilov V; Sivertsson R
    Int J Clin Pharmacol Ther Toxicol; 1984 Feb; 22(2):91-5. PubMed ID: 6421758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Plasma levels of nitroglycerin after oral and percutaneous administration (author's transl)].
    Girre C; Crouzette J; Fournier PE
    Nouv Presse Med; 1980 Sep; 9(34 Suppl):2433-6. PubMed ID: 6775295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of topical nitroglycerin on transcutaneous oxygen.
    Romanelli M; Katz MH; Alvarez AF; Eaglstein WH; Falanga V
    Br J Dermatol; 1991 Apr; 124(4):354-7. PubMed ID: 1902742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma nitroglycerin levels, blood pressure and apical heart rate variations to site of application of nitroglycerin ointment.
    Conant CC
    Nurse Pract; 1988 Oct; 13(10):56, 58, 63-4. PubMed ID: 3147433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic levels of glyceryl trinitrate following topical application to the anoderm do not correlate with the measured reduction in anal pressure.
    Jonas M; Barrett DA; Shaw PN; Scholefield JH
    Br J Surg; 2001 Dec; 88(12):1613-6. PubMed ID: 11736974
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism.
    Wester RC; Noonan PK; Smeach S; Kosobud L
    J Pharm Sci; 1983 Jul; 72(7):745-8. PubMed ID: 6411893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nitroglycerin ointment - a drug with sustained efficacy in angina pectoris.
    Singh S; Agarwal BL; Kumar K; Misra A; Shukla SK; Shukla SR
    J Assoc Physicians India; 1982 Apr; 30(4):219-21. PubMed ID: 6820655
    [No Abstract]   [Full Text] [Related]  

  • 54. Nitroglycerin levels after administration via transdermal therapeutic system or as ointment.
    Hirtz J; Imhof PR; Hauser PF
    Lancet; 1984 Sep; 2(8403):633. PubMed ID: 6147658
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparison of two transdermal nitroglycerin systems.
    Godoy C; Greenspahn BR; Kushner MJ; Lahti RE; Levy RA; Reese P; Reynolds GM; Rice SC
    Clin Ther; 1986; 8(6):689-93. PubMed ID: 3098427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin.
    Nakashima E; Noonan PK; Benet LZ
    J Pharmacokinet Biopharm; 1987 Aug; 15(4):423-37. PubMed ID: 3119815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relative effectiveness of nitroglycerin ointment according to site of application.
    Hansen MS; Woods SL; Wills RE
    Heart Lung; 1979; 8(4):716-20. PubMed ID: 110729
    [No Abstract]   [Full Text] [Related]  

  • 58. Transcutaneous nitroglycerin--ointment or disc?
    Abrams J
    Am Heart J; 1984 Dec; 108(6):1597-600. PubMed ID: 6439020
    [No Abstract]   [Full Text] [Related]  

  • 59. [Transcutaneous application of nitroglycerin and isosorbide dinitrate versus placebo: effect in myocardial ischemia].
    Gloor HO; Angehrn W; Steinbrunn W
    Schweiz Med Wochenschr; 1985 Mar; 115(12):412-7. PubMed ID: 3922052
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative evaluation of the three commercially available transdermal nitroglycerin delivery systems.
    Cronin CM; Mitrano EA; Wilder RS; Harmon EP; Zusman RM
    Drug Intell Clin Pharm; 1987; 21(7-8):642-4. PubMed ID: 3111812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.